Prosensa Holding B.V. (RNA) 18.65 $RNA Prosensa

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Prosensa Holding B.V. (RNA) 18.65 $RNA

Prosensa Announces Voluntary Delisting and Advance Liquidation Distribution
GlobeNewswire - Tue Feb 10, 11:16AM CST
Prosensa Holding N.V. (Nasdaq:RNA) ("Prosensa" or the "Company", the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced today that, on February 11, 2015, it will file a Form 25, Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934 (the "Exchange Act" (the "Form 25", with the Securities Exchange Commission ("SEC" in order to voluntarily delist the registered shares of the Company, nominal value EUR0.01 per share (the "Shares" from the NASDAQ Global Select Market ("NASDAQ", which will become effective 10 days after filing. NASDAQ has advised the Company that it will suspend trading of the Shares after the market closes on February 11, 2015. As such, shareholders of the Company will not be able to trade their shares on NASDAQ thereafter.
BMRN: 100.25 (+0.83), RNA: 18.65 (unch)

Prosensa Announces Intent to Voluntarily Delist From NASDAQ
GlobeNewswire - Fri Jan 30, 7:36AM CST
Prosensa Holding N.V. (Nasdaq:RNA) ("Prosensa" or the "Company", the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced today that it intends to voluntarily delist the registered shares of the Company, nominal value EUR0.01 per share (the "Shares", from the NASDAQ Global Select Market ("NASDAQ". Upon satisfaction of the applicable requirements for deregistration, Prosensa also intends to deregister the Shares under the Securities Exchange Act of 1934, as amended (the "Exchange Act" and to suspend its reporting obligations under the Exchange Act once it is eligible to do so.
BMRN: 100.25 (+0.83), RNA: 18.65 (unch)

BioMarin Announces Final Results of Tender Offer for Prosensa's Shares and Completion of Subsequent Offering Period
GlobeNewswire - Fri Jan 30, 7:00AM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the final results of, and the completion of the subsequent offering period relating to, the previously announced tender offer by its subsidiaries, BioMarin Falcons B.V. and BioMarin Giants B.V. (together, "Purchaser", to acquire all of the outstanding ordinary shares of Prosensa Holding N.V. (Nasdaq:RNA) at a purchase price of $17.75 per share, net to the seller in cash (the "Cash Consideration", plus one non-transferrable contingent value right to receive cash payments of up to $4.14 per share in the aggregate upon the achievement of certain product approval milestones ("CVR", in each case, without interest thereon and less any applicable withholding taxes.
BMRN: 100.25 (+0.83), RNA: 18.65 (unch)

BioMarin to Raise Funds to Finance Prosensa Acquisition - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 5:00PM CST
BioMarin (BMRN) will be raising approximately $792.6 million through the issuance of the shares in order to finance the Prosensa acquisition.
BMRN: 100.25 (+0.83), RNA: 18.65 (unch), ALXN: 133.50 (+4.90), AMGN: 174.16 (+2.13)

3 Warning Signs You've Invested in a Dangerous Biotech Stock
Motley Fool Staff - Motley Fool - Sat Jan 17, 10:59AM CST
Source: Flickr user  epSos .de . There might not be a bell that will ring to alert investors when they have put their money in the wrong biotech stock, but there are warning signals that can help them avoid owning the most dangerous biotech...
INO: 10.42 (+0.54), BMRN: 100.25 (+0.83), RNA: 18.65 (unch), GSK: 45.25 (+0.18)

BioMarin Announces Completion of Tender Offer for Prosensa's Shares and Commences Subsequent Offering Period
GlobeNewswire - Thu Jan 15, 7:59AM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it completed the initial offering period for the previously announced tender offer for all of the outstanding ordinary shares of Prosensa Holding N.V. (Nasdaq:RNA). As a result, BioMarin will purchase approximately 93.4% of Prosensa's outstanding shares pursuant to the initial offering period for the tender offer. BioMarin also announced that it has commenced a subsequent offering period to provide Prosensa shareholders who have not yet tendered their shares the opportunity to do so. The subsequent offering period is scheduled to expire at 6:00 p.m., New York City time, on January 29, 2015.
BMRN: 100.25 (+0.83), RNA: 18.65 (unch)

BioMarin Gains on Vimizim 2014 View, Batten Disease Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 14, 4:10PM CST
BioMarin (BMRN) raised its 2014 guidance for Vimizim sales and presented encouraging interim data from an ongoing phase I/II pivotal study on Batten disease candidate, BMN 190.
BMRN: 100.25 (+0.83), RNA: 18.65 (unch), ALXN: 133.50 (+4.90), AMAG: 27.02 (+0.49)

Prosensa Announces Shareholder Approval of Certain Matters Relating to the BioMarin Tender Offer
GlobeNewswire - Tue Jan 13, 7:56AM CST
Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced that during an extraordinary general meeting of shareholders held today, Prosensa obtained shareholder approval for certain matters relating to the previously disclosed tender offer by BioMarin to purchase all of the outstanding shares of Prosensa.
RNA: 18.65 (unch)

Why Sarepta Therapeutics Inc. Stock Tumbled 15% in December
Sean Williams, The Motley Fool - Motley Fool - Fri Jan 09, 6:04AM CST
SRPT data by YCharts What: Shares of Sarepta Therapeutics , a clinical-stage biotechnology company primarily focused on developing therapies to treat Duchenne muscular dystrophy, or DMD, tumbled 15% in December according to data from ...
BMRN: 100.25 (+0.83), RNA: 18.65 (unch), SRPT: 25.91 (+0.63)

PTC Therapeutics Starts Rolling NDA Filing for Translarna - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:10PM CST
PTC Therapeutics (PTCT) initiated the process of a rolling submission of a new drug application to the FDA for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy.
RNA: 18.65 (unch), SRPT: 25.91 (+0.63), PTCT: 6.10 (+0.13), BIOD: 0.41 (-0.03)

BioMarin and Prosensa Announce Expiration of the Hart-Scott-Rodino Waiting Period for BioMarin's Proposed Acquisition of Prosensa
GlobeNewswire - Wed Dec 24, 12:15PM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) and Prosensa Holding N.V. (Nasdaq:RNA) today announced the expiration of the mandatory waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act", which occurred at 11:59 p.m. on December 23, 2014, with respect to BioMarin's pending acquisition of Prosensa.
BMRN: 100.25 (+0.83), RNA: 18.65 (unch)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

TIER IV Simplifies Autonomous Driving with CARLA 1.0

Updated Category News Views 63

No More Detours in Autonomous Development Ever messed with a puzzle that just won't fit until suddenly, it clicks? That's what TIER IV just pulled off with their latest work on CARLA 1.0, the open-source simulator. There's no more mucking about with that separate Python-based bridge to get things communicating—now we're talking native Autoware support. A direct line to...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 83

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
Visa Direct Tests Stablecoin Prefunding in Asia-Pacific

Updated Category News Views 167

Cross-border payouts have always had an ugly little problem: money can move digitally in theory, then sit around waiting for banks to wake up in practice. Triple-A’s new collaboration with Visa Direct aims straight at that nuisance in Asia-Pacific, allowing eligible clients to use stablecoins to prefund cross-border payouts while the recipient still gets local currency....

Continue Reading
Oracle Takes AI to Construction's Messy Project Middle

Updated Category News Views 17

A stalled drywall inspection can wreck a schedule faster than any glossy AI pitch can repair it. That is the grimy, practical corner Oracle is aiming at with its latest Oracle Primavera Cloud upgrades: the daily hunt for answers, the repeated logging of familiar risks, and the finger-pointing that starts when a milestone is suddenly in danger. This is not a chatbot being...

Continue Reading
Three Cash Buyouts Draw Fresh Shareholder Scrutiny

Updated Category News Views 149

Three cash-price tags landed on the tape with a lawyerly asterisk attached: are public holders actually getting a fair shake? On November 18, 2026, Halper Sadeh LLC said it was investigating proposed sales involving Surgery Partners, Braze and CCC Intelligent Solutions. That is not a finding of misconduct, and investors ought to keep that distinction bolted firmly to the...

Continue Reading
Qonto's Banking License Raises the Stakes in Europe

Updated Category News Views 56

A regulatory stamp can look dull on paper, yet this one changes the machinery underneath Qonto. The Paris-based finance platform has received a Credit Institution license from France's ACPR and the European Central Bank, giving it a route to offer broader lending and savings products directly to small and midsize businesses across Europe. That is a serious corporate...

Continue Reading
Luxury's €1.5 Trillion Market Has Moved to Memories

Updated Category News Views 36

A €1.5 trillion market that cannot grow much is still a market worth fighting over, but luxury's old playbook is looking awfully tired. Bain's 2026 view is for global luxury spending to land somewhere between flat and up 2% at constant exchange rates versus 2025. That is stability, not a victory parade. Yet the total market remains 16% to 22% above 2019 levels, and the...

Continue Reading
Vusion's 2030 Plan Puts Recurring Revenue First At Scale

Updated Category News Views 30

Shelf labels are not exactly romance, yet Vusion has turned them into a serious growth machine. The 2030 plan is not really about hanging more electronic displays in aisles; it is about making those displays, sensors and store connections produce software and service revenue for years. That is the part of this story worth watching. The Hardware Base Is Becoming the Hook...

Continue Reading
Clorox Boosts Payout With Steady $1.25 Dividend

Updated Category News Views 205

Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...

Continue Reading
Visual Cipher Bench Exposes AI Agents' Hidden Rule Gap

Updated Category News Views 0

Forty little black-and-white puzzles just threw a bucket of cold water on the autonomous-agent sales pitch. Einsia AI’s Navers Lab says its new Visual Cipher Bench found that the best result among eight frontier models was only 26.7%, with no tested configuration clearing 30%. That is not a minor blemish. It is a reminder that a model can sound clever, use tools, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Class Action Alert: KBR, Inc. Investors Should Take Note

Updated Category News Views 351

Class Action Alert for KBR, Inc. Investors Attention to all stakeholders of KBR, Inc. (NYSE: KBR): there has been significant news affecting your investments. A class action lawsuit is underway, compelling shareholders to reflect on the recent allegations against the company. Amidst claims of misleading communications concerning a crucial contract, KBR's stock has been...

Continue Reading
PyroGenesis Reports Q3 2025 Performance and Future Outlook

Updated Category News Views 192

Financial Insights from PyroGenesis' Q3 2025 PyroGenesis Inc. (TSX:PYR), a frontrunner in plasma-based technologies for heavy industry and defense, has unveiled its financial and operational results for the third quarter of 2025. This report highlights a revenue of $3.25 million, which reflects an 18.7% decline from the same period last year. This downturn is attributed...

Continue Reading
Metacon Reports Remarkable Revenue Growth in Q1 2025

Updated Category News Views 443

Metacon Achieves Significant Financial Milestones in Q1 2025 The first quarter of 2025 has marked an exciting chapter for Metacon, showcasing remarkable progress both financially and operationally. During this period, the company realized net sales of SEK 50 million, a substantial increase compared to SEK 8.3 million in the same quarter last year. This remarkable growth...

Continue Reading
Revolutionizing Workplace Productivity with Humanyze Insights

Updated Category News Views 106

Transforming the Workforce with AI-Driven Insights Humanyze, a pioneer in workforce analytics, recently unveiled Humanyze Insights, a cutting-edge platform specifically designed to enhance workforce productivity, drive profitability, and inspire sustainable growth for organizations. This AI-powered solution signifies a notable evolution from Humanyze’s previous...

Continue Reading
SKE Invigorates IRONWORKS London's Music Vibe With E-Cigs

Updated Category News Views 646

Bringing SKE's Flair to London's Music Scene Well, folks, hold onto your hats—SKE's thrown its weight behind IRONWORKS London, extending its reach deeper into the UK's electronic music scene. This ain't just another gig; we're talking about the second time SKE is flexing its sponsorship muscles in the UK music arena, officially angling for the vape category spotlight....

Continue Reading